Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221782 | 0.88 | NPC1 (0.32) | CYP1A2KDM4ENPC1RAB9A | |
| SCHEMBL3082762 | 0.75 | NPC1 (0.42) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL549435 | 0.71 | MAPT (0.50) | CYP19A1KDM4ENPC1RAB9AMAPT | |
| SCHEMBL5333405 | 0.67 | FYN (0.37) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL28450892 | 0.67 | KMO (0.34) | — | |
| Methoxymethane SCHEMBL27908243 | 0.66 | RAB9A (0.50) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL3809697 | 0.65 | — | — | |
| SCHEMBL3854174 | 0.65 | KDM4A (0.42) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL157686 | 0.65 | CYP1A2 (0.32) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL27881782 | 0.65 | RAB9A (0.42) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344486-B1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THEIR USE AS FAAH INHIBITORS | SANOFI SA (FR) | 2013-03-27 | — | — | EP | claimed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | claimed |
| US-20070191400-A1 | Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives | RIMONYX PHARMACEUTICALS LTD. (IL) | 2007-08-16 | — | — | US | claimed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | claimed |
| EP-1740176-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-INFLAMMATORY QUINAZOLINECARBOXAMIDE DERIVATIVES | Rimonyx Pharmaceuticals Ltd. (IL) | 2007-01-10 | — | — | EP | claimed |
| WO-2005089068-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-INFLAMMATORY QUINAZOLINECARBOXAMIDE DERIVATIVES | RIMONYX PHARMACEUTICALS LTD. (IL) | 2005-09-29 | — | — | WO | claimed |
| CN-118284082-A | Light emitting device, electronic device including the same, and electronic apparatus including the same | 三星显示有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-4355426-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-04-24 | — | — | EP | disclosed |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| EP-1070058-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | Pfizer Products Inc. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000038680-A1 | AZABICYCLOALKANES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| US-6022976-A | Process for the production of 5-hydroxyoxazolidinones | ZENECA LIMITED | 2000-02-08 | — | — | US | disclosed |
| WO-1999052889-A1 | (4-ARYLSULFONYLAMINO)-TETRAHYDROPYRAN-4-CARBOXYLIC ACID HYDROXAMIDES | PFIZER PRODUCTS INC. (US) | 1999-10-21 | — | — | WO | disclosed |
| EP-0906318-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997045432-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES AS 5-HT RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1997-12-04 | — | — | WO | disclosed |
| US-5296503-A | Administering orally | BAYER AKTIENGESELLSCHAFT (DE) | 1994-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | CYP1A2 2046/4885CYP2D6 1794/4885CYP19A1 3737/4885 |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | CYP1A2 3675/4885CYP2D6 3470/4885CYP19A1 2496/4885 |
| US-11851434-B2 | Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors | RET, BRAF, ROR1 | CYP1A2 3675/4885CYP2D6 3470/4885CYP19A1 2496/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | CYP1A2 3559/4885CYP2D6 3420/4885CYP19A1 2427/4885 |
| US-20070191400-A1 | Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives | HPSE, SSB, HCLS1 | CYP1A2 2461/4885CYP2D6 2382/4885CYP19A1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.